DE60230624D1 - Thiolalkylbezoesäurederivate - Google Patents

Thiolalkylbezoesäurederivate

Info

Publication number
DE60230624D1
DE60230624D1 DE60230624T DE60230624T DE60230624D1 DE 60230624 D1 DE60230624 D1 DE 60230624D1 DE 60230624 T DE60230624 T DE 60230624T DE 60230624 T DE60230624 T DE 60230624T DE 60230624 D1 DE60230624 D1 DE 60230624D1
Authority
DE
Germany
Prior art keywords
activity
compounds
effecting
inhibiting
naaladase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230624T
Other languages
German (de)
English (en)
Inventor
Takashi Tsukamoto
Doris Stoermer
Dilrukshi Vitharana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Guilford Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc filed Critical Guilford Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60230624D1 publication Critical patent/DE60230624D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DE60230624T 2001-05-30 2002-05-30 Thiolalkylbezoesäurederivate Expired - Lifetime DE60230624D1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29403601P 2001-05-30 2001-05-30
US34274601P 2001-12-28 2001-12-28
PCT/US2002/016971 WO2002096866A2 (en) 2001-05-30 2002-05-30 Thiolalkyl benzoic acid derivatives

Publications (1)

Publication Number Publication Date
DE60230624D1 true DE60230624D1 (en) 2009-02-12

Family

ID=26968313

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60230624T Expired - Lifetime DE60230624D1 (en) 2001-05-30 2002-05-30 Thiolalkylbezoesäurederivate

Country Status (13)

Country Link
US (2) US6740777B2 (enExample)
EP (2) EP2025666A3 (enExample)
JP (2) JP4292471B2 (enExample)
AT (1) ATE419232T1 (enExample)
AU (1) AU2002310202B2 (enExample)
CA (1) CA2448089C (enExample)
CY (1) CY1108893T1 (enExample)
DE (1) DE60230624D1 (enExample)
DK (1) DK1406867T3 (enExample)
ES (1) ES2319509T3 (enExample)
MX (1) MXPA03010859A (enExample)
PT (1) PT1406867E (enExample)
WO (1) WO2002096866A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265111A1 (en) * 2000-05-30 2001-12-11 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
MXPA03010859A (es) * 2001-05-30 2004-02-17 Guilford Pharm Inc Derivados de acido tioalquilbenzoico.
US7148250B2 (en) * 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
DE602004021476D1 (de) * 2003-03-03 2009-07-23 Eisai Corp North America THIOLACTONE ALS NAALADase INHIBITOREN
US20040186081A1 (en) * 2003-03-03 2004-09-23 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating opioid tolerance
WO2004101483A1 (ja) * 2003-05-14 2004-11-25 Riken 新規3置換ベンゼン誘導体、その製造方法、およびそれを含む医薬組成物
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
US7282590B2 (en) 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
EP2299999B1 (en) * 2008-06-04 2017-08-16 Baylor College Of Medicine Stat3 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3053890A (en) * 1960-03-31 1962-09-11 California Research Corp Reaction products of formaldehyde and o-mercaptomethylbenzoic acid
US4318846A (en) * 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US5089388A (en) 1983-04-19 1992-02-18 Syntex (U.S.A.) Inc. Antibodies for salicylate and their preparation
US5314918A (en) 1987-06-24 1994-05-24 Smithkline Beecham Corporation Leukotriene antagonists
US5204358A (en) 1987-11-25 1993-04-20 Merck Frosst Canada, Inc. Hetaryl styryl quinolines as leukotriene inhibitors
US5258551A (en) 1991-12-18 1993-11-02 Shionogi & Co., Ltd. Process for producing α-ketoamide derivative
US5409780A (en) 1992-02-13 1995-04-25 Chemtrak, Inc. Aniline analogs for hydrogen peroxide detection
US5316887A (en) 1992-07-31 1994-05-31 Polaroid Corporation Thermally developable photosensitive material
US5453502A (en) 1994-03-16 1995-09-26 Eli Lilly And Company 1,3,4 substituted and bicyclic derivatives of 2-azetidinones and processes for preparation thereof
AR006793A1 (es) 1996-04-26 1999-09-29 Ishihara Sangyo Kaisha Compuestos pirazol o sus sales y herbicidas conteniendo los mismos
US6025344A (en) * 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
MXPA01000144A (es) * 1998-07-06 2002-10-17 Guilford Pharm Inc Inhibidores de naaladasa utiles como composiciones y compuestos farmaceuticos.
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
JP5095050B2 (ja) * 1999-04-28 2012-12-12 ジョージタウン ユニバーシティー 代謝調節型グルタミン酸受容体のリガンド、及び、NAALADaseの阻害剤
WO2001092274A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating retinal disorders and glaucoma
US20020013295A1 (en) 2000-05-30 2002-01-31 Slusher Barbara S. Naaladase inhibitors for treating amyotrophic lateral sclerosis
AU2001265111A1 (en) 2000-05-30 2001-12-11 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
MXPA03010859A (es) * 2001-05-30 2004-02-17 Guilford Pharm Inc Derivados de acido tioalquilbenzoico.

Also Published As

Publication number Publication date
US20030100607A1 (en) 2003-05-29
WO2002096866A3 (en) 2004-01-15
MXPA03010859A (es) 2004-02-17
US6740777B2 (en) 2004-05-25
JP2009149657A (ja) 2009-07-09
AU2002310202B2 (en) 2008-05-15
EP1406867A2 (en) 2004-04-14
EP2025666A3 (en) 2010-03-31
CA2448089C (en) 2010-10-19
EP1406867B1 (en) 2008-12-31
EP2025666A2 (en) 2009-02-18
WO2002096866A2 (en) 2002-12-05
US7138543B2 (en) 2006-11-21
JP2005503353A (ja) 2005-02-03
CY1108893T1 (el) 2014-07-02
CA2448089A1 (en) 2002-12-05
PT1406867E (pt) 2009-02-25
JP4292471B2 (ja) 2009-07-08
ATE419232T1 (de) 2009-01-15
ES2319509T3 (es) 2009-05-08
US20040198824A1 (en) 2004-10-07
DK1406867T3 (da) 2009-04-06

Similar Documents

Publication Publication Date Title
WO2003057670A3 (en) Indoles as naaladase inhibitors
CY1108893T1 (el) Παραγωγα θειοαλκυλ βενζοϊκου οξεος
WO2001092273A3 (en) Benzenedicarboxylic acid derivatives
WO2002057222A3 (en) Thiol-based naaladase inhibitors
WO2001014390A3 (en) METABOTROPIC GLUTAMATE RECEPTOR LIGAND DERIVATIVES AS NAALADase INHIBITORS
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
IL159300A0 (en) Prodrugs of gaba analogs, compositions and uses thereof
WO2005025511A3 (en) Potassium channel mediated delivery of agents through the blood-brain barrier
MXPA03010328A (es) Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa.
ATE432923T1 (de) 5-aminoindenoä1,2-cüpyrazol-4-one als antitumor- und wachstumshemmende mittel
CA2337797A1 (en) Naaladase inhibitors useful as pharmaceutical compounds and compositions
WO2002059373A3 (en) Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2001034596A3 (en) Pyrrolecarbonylimino derivatives as naaladase inhibitors
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
CY1109356T1 (el) Θειολακτονες ως αναστολεις της νααladασης
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO2002074756A3 (de) Urokinase-inhibitoren
WO2003050504A3 (en) Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201
EP1958939A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2003037260A3 (en) Methods and compositions for treating parkinson's disease
WO2005000406A3 (en) Treatment of amyloid- and epileptogenesis-associated diseases
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
WO2004071411A3 (en) Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620
WO2003053364A3 (en) Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
WO2003039342A3 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MGI GP, INC., BALTIMORE, MD., US

8327 Change in the person/name/address of the patent owner

Owner name: EISAI CORPORATION OF NORTH AMERICA, WOODCLIFF , US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EISAI INC., WOODCLIFF LAKE, N.J., US